ATE144326T1 - Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes - Google Patents

Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Info

Publication number
ATE144326T1
ATE144326T1 AT91917268T AT91917268T ATE144326T1 AT E144326 T1 ATE144326 T1 AT E144326T1 AT 91917268 T AT91917268 T AT 91917268T AT 91917268 T AT91917268 T AT 91917268T AT E144326 T1 ATE144326 T1 AT E144326T1
Authority
AT
Austria
Prior art keywords
idd
dependent diabetes
early detection
insulin
detection
Prior art date
Application number
AT91917268T
Other languages
English (en)
Inventor
Mark A Atkinson
Noel K Maclaren
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE144326T1 publication Critical patent/ATE144326T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
AT91917268T 1990-08-17 1991-08-16 Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes ATE144326T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56932490A 1990-08-17 1990-08-17

Publications (1)

Publication Number Publication Date
ATE144326T1 true ATE144326T1 (de) 1996-11-15

Family

ID=24274953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917268T ATE144326T1 (de) 1990-08-17 1991-08-16 Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Country Status (10)

Country Link
EP (1) EP0543945B1 (de)
JP (1) JP2649103B2 (de)
AT (1) ATE144326T1 (de)
AU (1) AU661828B2 (de)
CA (1) CA2089742C (de)
DE (1) DE69122761T2 (de)
DK (1) DK0543945T3 (de)
ES (1) ES2093714T3 (de)
GR (1) GR3022078T3 (de)
WO (1) WO1992003733A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
JP2727377B2 (ja) * 1990-09-07 1998-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病自己抗体の検出方法
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
DK0572478T3 (da) * 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
WO1992019972A1 (en) * 1991-05-03 1992-11-12 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
WO1992020811A2 (en) * 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
CA2074790A1 (en) * 1992-07-28 1994-01-29 H. Michael Dosch Methods for detecting pre-clinical iddm
DE69334246D1 (de) * 1992-12-03 2008-12-24 Univ California Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7008790B1 (en) 1993-08-12 2006-03-07 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
CN1157621A (zh) * 1994-07-08 1997-08-20 达特茅斯大学理事会 用于检测和治疗i型糖尿病的胰岛素原肽化合物
US6509165B1 (en) 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448635B1 (de) * 1988-12-13 1995-09-20 University Of Florida Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm)

Also Published As

Publication number Publication date
EP0543945A1 (de) 1993-06-02
WO1992003733A1 (en) 1992-03-05
DE69122761T2 (de) 1997-03-13
AU8544891A (en) 1992-03-17
JP2649103B2 (ja) 1997-09-03
GR3022078T3 (en) 1997-03-31
AU661828B2 (en) 1995-08-10
JPH06500173A (ja) 1994-01-06
CA2089742A1 (en) 1992-02-18
DK0543945T3 (da) 1997-03-24
ES2093714T3 (es) 1997-01-01
DE69122761D1 (de) 1996-11-21
EP0543945B1 (de) 1996-10-16
CA2089742C (en) 2002-05-14

Similar Documents

Publication Publication Date Title
DE69122761D1 (de) Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
CA2005300A1 (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO904001D0 (no) Fremgangsmaate og anordning for amperometrisk diagnoseanalyse.
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
ATE163767T1 (de) Verfahren zur diagnose und zur überprüfung von sepsis
DE69828645D1 (de) Gerät zur entnahme von interstitiellen flüssigkeit für diagnostische teste
ATE210296T1 (de) Immunologisches nachweisverfahren von antikörpern,die gegen gewebe-transglutaminase (ttg) gerichtet sind, verwendung von ttg zur diagnose und therapiekontrolle sowie orales pharmazeutisches mittel enthaltend ttg
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
NZ510703A (en) Assay for disease related conformation of a protein
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE69032833D1 (de) Diagnose und behandlung von insulinabhängigem diabetes mellitus
Westhoff et al. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients
JP2001513533A5 (de)
DE69230890D1 (de) Bestimmung von nukleären matrixproteinen in flüssigkeiten
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
DK0568554T3 (da) Fremgangsmåde til påvisning af anti-RNA-antistoffer
FI951778A0 (fi) Menetelmä allergian toteamiseksi
DE69224795D1 (de) 4Verfahren und Zusammensetzungen zur Vorbeugung, Diagnose und Behandlung seröser Entzündungen und damit verbundener Störungen
ATE80465T1 (de) Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.
UA34212A (uk) Спосіб оцінки результатів лікування хворих на ранні форми сифілісу
Jinkins Atonement and the character of God: a comparative study in the theology of atonement in Jonathan Edwards and John McLeod Campbell
Morris Recovering from coronary artery bypass graft surgery: Do depression, optimism, and coping predict quality of recovery?
ATE130099T1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
Chuang et al. Clinical Evaluation of Patients with Shoulder Pain
UA13923A (uk) Спосіб дифереhційhої діагhостики підтипів іhсуліhhезалежhого цукрового діабету

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee